Spotlight on Internal Medicine

Credits: 0.25 AAPA / CME / CPE
Optimizing Diagnosis and Management of Nontuberculous Mycobacterial Lung Disease—NTM Lung Disease Curbside Consults: Treatment Optimization - New Guidelines for NTM-LD Management
David E. Griffith, MD, FACP, FCCP, ATSF
Vindico

Optimizing Diagnosis and Management of Nontuberculous Mycobacterial Lung Disease—NTM Lung Disease Curbside Consults: Treatment Optimization - New Guidelines for NTM-LD Management

Start

Activity Details

Free CME/CPE/AAPA
0.25 AMA PRA Category 1 Credit(s)
0.25 ACPE Contact Hour(s)
0.25 AAPA Category 1 CME Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Identify patients with nontuberculous mycobacterial lung disease (NTM-LD) using knowledge of the pathophysiology; environmental factors; underlying conditions (eg, bronchiectasis); and risk factors.
  • Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.

Activity Description

In this Curbside Consult, Drs. David Griffith and Charles Daley discuss workup, management, and follow-up of NTM lung disease in a 60-year-old woman presenting with cough, fatigue, mild dyspnea, and weight loss.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-004-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202343.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE/AAPA
0.25 AMA PRA Category 1 Credit(s)
0.25 ACPE Contact Hour(s)
0.25 AAPA Category 1 CME Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Identify patients with nontuberculous mycobacterial lung disease (NTM-LD) using knowledge of the pathophysiology; environmental factors; underlying conditions (eg, bronchiectasis); and risk factors.
  • Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.

Activity Description

In this Curbside Consult, Drs. David Griffith and Charles Daley discuss workup, management, and follow-up of NTM lung disease in a 60-year-old woman presenting with cough, fatigue, mild dyspnea, and weight loss.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-004-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202343.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CE
Clinical Care Options
Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Start

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com

1.00 CME / CE
Vindico
Recent Advances in the Management of Psoriasis

Recent Advances in the Management of Psoriasis

Start

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit(s)
AANP Contact Hours
AAPA Category 1 CME credit
Released: December 31, 2020
Expires: December 30, 2021
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Review the pathophysiology and comorbidities associated with psoriasis.
  • Apply current guideline-directed recommendations to the management of patients with psoriasis.
  • Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
  • Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.

Activity Description

Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.

Activity Co-Chairs

Mark Lebwohl, MD
Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB


Linda F. Stein Gold, MD
Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI

Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124656. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201757.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.

MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit(s)
AANP Contact Hours
AAPA Category 1 CME credit
Released: December 31, 2020
Expires: December 30, 2021
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with psoriasis.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Review the pathophysiology and comorbidities associated with psoriasis.
  • Apply current guideline-directed recommendations to the management of patients with psoriasis.
  • Incorporate the latest clinical data, including efficacy and safety of topical treatments and biologics, in therapeutic decision-making to individualize care of patients with psoriasis.
  • Implement effective strategies for clinician-patient communication to address patient concerns, treatment expectations, and the importance of adherence to therapy to promote health-related quality of life for patients.

Activity Description

Psoriasis is a chronic, inflammatory skin condition that can significantly impact a patient’s quality of life (QoL). Unfortunately, many patients with psoriasis do not seek treatment, are undertreated, or do not adhere to traditional treatment protocols. Furthermore, patients with psoriasis are at an increased risk for other serious illnesses and depression. Clinical studies have demonstrated the safety and efficacy of biologic therapies in patients with moderate to severe psoriasis, and these therapies have provided high degrees of disease improvement. In this CE activity, experts in the field will review the pathophysiology of psoriasis and its associated comorbidities, discuss current guideline-directed recommendations for the management of patients, and evaluate the latest clinical data regarding therapeutic decision-making to individualize care. They will also provide insight for effective strategies to enhance clinician-patient communication, address patients’ concerns, treatment expectations, and the importance of adherence to therapy to promote health-related QoL.

Activity Co-Chairs

Mark Lebwohl, MD
Professor and Chairman/Kimberly & Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure:
Consulting Fee: Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, EMD Serono, Evelo Biosciences, Facilitation of International Dermatology Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharmaceuticals, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Theravance, Verrica
Contracted Research: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Incyte, Janssen Research & Development, LEO Pharmaceuticals, Lilly, Ortho Dermatologics, Pfizer, UCB


Linda F. Stein Gold, MD
Director of Clinical Research, Department of Dermatology
Henry Ford Health System
Detroit, MI

Disclosure:
Consulting Fee: AbbVie, Amgen, Arcutis, Dermavant, LEO Pharmaceuticals, Lilly, Novartis, Ortho Dermatologics
Speakers Bureau: Amgen, Ortho Dermatologics

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124656. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 12/31/2020 to 12/30/2021. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201757.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, Contact Hours Certificate, or AAPA Category 1 CME Certificate.

MIPS Qualifying Activity
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the Merit-based Incentive Payment System (MIPS) of Quality Payment Program (QPP), CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME / MOC
Vindico
Complicating Factors in Pediatric Rheumatology: Managing Influenza

Complicating Factors in Pediatric Rheumatology: Managing Influenza

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™/ ABP MOC Part 2
Released: December 31, 2020
Expires: December 30, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
  • Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.

Agenda

Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Treating Influenza in Pediatric Patients With Rheumatic Disease
Stan L. Block, MD, FAAP

Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Activity Chair

Timothy Beukelman, MD, MS, MSCE
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL

Disclosure:
Consulting Fee: Novartis, UCB


Faculty

Stan L. Block, MD, FAAP
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY

Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi


Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™/ ABP MOC Part 2
Released: December 31, 2020
Expires: December 30, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
  • Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.

Agenda

Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Treating Influenza in Pediatric Patients With Rheumatic Disease
Stan L. Block, MD, FAAP

Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Activity Chair

Timothy Beukelman, MD, MS, MSCE
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL

Disclosure:
Consulting Fee: Novartis, UCB


Faculty

Stan L. Block, MD, FAAP
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY

Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi


Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

1.00 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum℠

Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum℠

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/ABIM MOC point(s)
Released: December 30, 2020
Expires: December 29, 2021
60 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This activity is designed for infectious disease, critical care, and primary care clinicians.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
  • Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
  • Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections

Activity Description

During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.

Statement of Educational Need

Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.

Faculty

Chair
Thomas Lodise, PharmD, PhD
Professor
Department of Pharmacy 
Albany College of Pharmacy and Health Services 
Albany, NY 


Joseph Reilly, BS, PharmD, BCGP
Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ


Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP
Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada


Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta, Shionogi Inc. (Speakers Bureau)

Joseph Reilly, BS, PharmD, BCGP, has affiliations with:
Cumberland, Melinta (Speakers Bureau)

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has affiliations with:
Sunovion (Speakers Bureau)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical Director, has no financial relationships to disclose.
Sharon Powell, Editor, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Accreditation Statement

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Melinta Therapeutics, Inc.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/ABIM MOC point(s)
Released: December 30, 2020
Expires: December 29, 2021
60 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This activity is designed for infectious disease, critical care, and primary care clinicians.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
  • Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
  • Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections

Activity Description

During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.

Statement of Educational Need

Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.

Faculty

Chair
Thomas Lodise, PharmD, PhD
Professor
Department of Pharmacy 
Albany College of Pharmacy and Health Services 
Albany, NY 


Joseph Reilly, BS, PharmD, BCGP
Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ


Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP
Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada


Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta, Shionogi Inc. (Speakers Bureau)

Joseph Reilly, BS, PharmD, BCGP, has affiliations with:
Cumberland, Melinta (Speakers Bureau)

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has affiliations with:
Sunovion (Speakers Bureau)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical Director, has no financial relationships to disclose.
Sharon Powell, Editor, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Accreditation Statement

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Melinta Therapeutics, Inc.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

1.00 CME
Integrity Continuing Education, Inc.
Redefining the Diagnosis and Therapy of COPD: Lessons from COPDGene, GOLD Reports, and Precision Medicine

Redefining the Diagnosis and Therapy of COPD: Lessons from COPDGene, GOLD Reports, and Precision Medicine

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 21, 2020
Expires: December 21, 2021
1 hour to complete

Accredited By

Target Audience

This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with COPD.

Learning Objectives

  • Identify clinical, functional, and radiological characteristics that can facilitate earlier COPD diagnosis and recognition of those who can benefit from available therapies​
  • Recognize the importance of smoking cessation, early treatment, and other prevention approaches in alleviating the burden of COPD​
  • Apply precision medicine-based approaches and current GOLD strategy to improve individualized treatment of COPD​
  • Describe the ongoing evolution of COPD diagnosis and its management in the era of COVID-19

Statement of Educational Need

Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, clinical practice has consistently underdiagnosed and undertreated this condition. As a result, patients with COPD continue to be associated with a poor quality of life, and there has remained an unmet need to improve its continuum of care. Recent data have shown that, using new criteria and methodologies, the definition of COPD can be broadened to include patients who would have been excluded from a previously characterized definite diagnosis. In addition, earlier treatment of such patients with pharmacologic, non-pharmacologic, and preventive strategies would be of benefit in reducing the burden of symptoms. Furthermore, implementation of updated guidelines and novel precision medicine-based approaches to individualize management of diverse patients with COPD will also be critical to improving outcomes. This continuing education program will clarify the clinical implications of new perspectives in the diagnosis, treatment, and management of this complicated disease.

Faculty

Gerard Criner, MD, FACP, FACCP
Professor of Medicine
Chair, Department of Thoracic Medicine & Surgery
Lewis Katz School of Medicine
Temple University Co-Director, Center for Inflammation and Lung Research
Medical Director, Pulmonary Service Line
Temple University Hospital
Philadelphia, Pennsylvania


Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York


Ruth Tal-Singer, PhD
President and Chief Scientific Officer
COPD Foundation
Washington, District of Columbia
President, TALSi Translational Medicine Consulting, LLC
Greater Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Gerard Criner, MD, FACP, FACCP
Consulting Fees: Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, Eolo Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Philips Respironics, Respivant Sciences, The Implementation Group, Verona Pharma ​

Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron​
Contracted Research: Afferent/Merck, Bayer, Biogen, Gilead, GlaxoSmithKline, Respivant Science, ProMedior/Roche, Veracyte​

Ruth Tal-Singer, PhD 
Former employee and current shareholder of GSK and reports personal fees from Vocalis Health, ImmunoMet, and Ena Respiratory. 

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of December 21, 2020 through December 21, 2021, participants must:

  • Read the learning objectives and faculty disclosures 
  • Complete the pretest
  • Study the educational activity 
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from AstraZeneca.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 21, 2020
Expires: December 21, 2021
1 hour to complete

Accredited By

Target Audience

This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with COPD.

Learning Objectives

  • Identify clinical, functional, and radiological characteristics that can facilitate earlier COPD diagnosis and recognition of those who can benefit from available therapies​
  • Recognize the importance of smoking cessation, early treatment, and other prevention approaches in alleviating the burden of COPD​
  • Apply precision medicine-based approaches and current GOLD strategy to improve individualized treatment of COPD​
  • Describe the ongoing evolution of COPD diagnosis and its management in the era of COVID-19

Statement of Educational Need

Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, clinical practice has consistently underdiagnosed and undertreated this condition. As a result, patients with COPD continue to be associated with a poor quality of life, and there has remained an unmet need to improve its continuum of care. Recent data have shown that, using new criteria and methodologies, the definition of COPD can be broadened to include patients who would have been excluded from a previously characterized definite diagnosis. In addition, earlier treatment of such patients with pharmacologic, non-pharmacologic, and preventive strategies would be of benefit in reducing the burden of symptoms. Furthermore, implementation of updated guidelines and novel precision medicine-based approaches to individualize management of diverse patients with COPD will also be critical to improving outcomes. This continuing education program will clarify the clinical implications of new perspectives in the diagnosis, treatment, and management of this complicated disease.

Faculty

Gerard Criner, MD, FACP, FACCP
Professor of Medicine
Chair, Department of Thoracic Medicine & Surgery
Lewis Katz School of Medicine
Temple University Co-Director, Center for Inflammation and Lung Research
Medical Director, Pulmonary Service Line
Temple University Hospital
Philadelphia, Pennsylvania


Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York


Ruth Tal-Singer, PhD
President and Chief Scientific Officer
COPD Foundation
Washington, District of Columbia
President, TALSi Translational Medicine Consulting, LLC
Greater Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Gerard Criner, MD, FACP, FACCP
Consulting Fees: Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, Eolo Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Philips Respironics, Respivant Sciences, The Implementation Group, Verona Pharma ​

Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron​
Contracted Research: Afferent/Merck, Bayer, Biogen, Gilead, GlaxoSmithKline, Respivant Science, ProMedior/Roche, Veracyte​

Ruth Tal-Singer, PhD 
Former employee and current shareholder of GSK and reports personal fees from Vocalis Health, ImmunoMet, and Ena Respiratory. 

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of December 21, 2020 through December 21, 2021, participants must:

  • Read the learning objectives and faculty disclosures 
  • Complete the pretest
  • Study the educational activity 
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from AstraZeneca.

0.50 CME
Academy for Continued Healthcare Learning
What Have We Learned? The Neverending Story of COVID-19 and ILD

What Have We Learned? The Neverending Story of COVID-19 and ILD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: December 10, 2020
Expires: December 10, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
  • Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
  • Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS

Activity Description

What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!

Statement of Educational Need

Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.

Faculty

Tanzira Zaman, MD
Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.

Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.

As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.

As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: December 10, 2020
Expires: December 10, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
  • Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
  • Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS

Activity Description

What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!

Statement of Educational Need

Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.

Faculty

Tanzira Zaman, MD
Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.

Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.

As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.

As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

Pages